QT interval prolongation and the risk of torsades de pointes: Essentials for clinicians

Current Medical Research and Opinion

Volumn 29, Issue 12, 2013, Pages 1719-1726

  Trinkley, Katy E ^a   Lee Page II, Robert ^a   Lien, Hoang ^a   Yamanouye, Kevin ^a   Tisdale, James E ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Drug induced; Mitigation; Prevention; QT interval prolongation; Risk factors; Torsades de pointes

Indexed keywords

AMANTADINE; AMIODARONE; AMITRIPTYLINE; ASTEMIZOLE; AZITHROMYCIN; CHLORPROMAZINE; CIPROFLOXACIN; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; CLOZAPINE; CYTOCHROME P450; DIPHENHYDRAMINE; DOFETILIDE; DOXEPIN; ERYTHROMYCIN; ESCITALOPRAM; FLUCONAZOLE; FLUOXETINE; GRANISETRON; HALOPERIDOL; IBUTILIDE; KETOCONAZOLE; LEVOFLOXACIN; METHADONE; MOXIFLOXACIN; ONDANSETRON; PIMOZIDE; TERFENADINE; UNINDEXED DRUG;

AGING; BRADYCARDIA; DIZZINESS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; ECG ABNORMALITY; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE BLOOD LEVEL; ENZYME INHIBITION; FAINTNESS; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; PATIENT EDUCATION; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; PREDICTION; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; SYMPTOM; TELEMETRY; TORSADE DES POINTES;

ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; PUBMED; RISK FACTORS; SEX FACTORS; TORSADES DE POINTES;

EID: 84888590663     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.840568     Document Type: Review

References (34)

1. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010;121:1047-60
2. Ritter JM. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacology 2012;73:331-4
3. Yap TG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72 (Pubitemid 37311108)
4. Tisdale JE, Wroblewski HA, Overholser BR, et al. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT-interval prolonging drugs. Drug Safety 2012;35:459-70
5. Tisdale JE. Ventricular arrhythmias. In: Tisdale JE, Miller DA (eds). Drug-induced diseases. Prevention, detection and management, 2nd edn. Bethesda: American Society of Health-System Pharmacists, 2010:485-515
6. Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891-9 (Pubitemid 46809861)
7. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84:1136-44
8. Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005;2:569-74 (Pubitemid 40724120)
9. Bazett HC. An analysis of the time-relations of electrocardiogram. Heart 1920;7:353-70
10. Trohman RG. Trust in technology: straddling the line between faith and reason. Crit Care Med 2010;38:712-13
11. Malik M, Färbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002;87:220-8 (Pubitemid 34177674)
12. Molnar J, Weiss J, Zhang F, et al. Evaluation of five QT correction formulas using a software-assisted method of continuous measurement from 24-hour Holter recordings. Am J Cardiol 1996;78:920-6 (Pubitemid 126658654)
13. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome: International Long-QT Syndrome Registry Research Group. N Engl J Med 1998;339:960-5 (Pubitemid 28455098)
14. European Medicines Agency. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500002879.pdf [Last accessed 18 February 2013]
15. Solomon R.The relationship between disorders of K+ and Mg+ homeostasis. Semin Nephrol 1987;7:253-62
16. Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs most patients have easily identifiable risk factors. Medicine 2003;82: 282-90 (Pubitemid 36859224)
17. Tester DJ, Will M, Haglund CM, et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 2006;47:764-8 (Pubitemid 43243098)
18. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT genes in patients with drug-associated torsades de pointes. Circulation 2002;105:1943-8 (Pubitemid 34437622)
19. Food and Drug Administration. Drug development and drug interactions: Table of substrates, inhibitors and inducers. 2011. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm093664.htm#classInhibit [Last accessed 18 February 2013]
20. Food and Drug Administration. FDA Drug Safety Communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm [Last accessed 18 February 2013]
21. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013;346:288-99
22. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmcoepidemiol Drug Saf 2005;14:747-53 (Pubitemid 41684467)
23. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Int Med 2009;150:387-95
24. McKechnie K, Froese Al. Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome. Can J Anesth 2010;57:453-7
25. Food and Drug Administration. FDA Drug Safety Communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm [Last accessed 18 February 2013]
26. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolar-ization prevents early after depolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303:218-25
27. Huang BH, Wu CH, Hsia CP, et al. Azithromycin-induced torsade de pointes. PACE 2007;30:1579-82
28. Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007;18:243-6 (Pubitemid 46944944)
29. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006;77:30-2
30. Samarendra PJ, Kumari A, Evans SJ, et al. QT prolongation associated with azithromycin/amiodarone combination. PACE 2001;24:1572-4 (Pubitemid 32977320)
31. Arellano-Rodrigo E, Garcia A, Mont L, et al. Torsade de pointes and cardio-respiratory arrest induced by azithromycin in a patient with congenital long QT syndrome. Med Clin 2001;117:118-19 (Pubitemid 32923820)
32. Kim MH, Berkoqitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol 2005;28:1221-2 (Pubitemid 43943010)
33. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. NEJM 2012;366:1881-90
34. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual 2013;6:479-87